192 related articles for article (PubMed ID: 26589521)
1. Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain.
Morales C; de Luis D; de Arellano AR; Ferrario MG; Lizán L
Diabetes Ther; 2015 Dec; 6(4):593-610. PubMed ID: 26589521
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
Tunis SL; Minshall ME; Conner C; McCormick JI; Kapor J; Yale JF; Groleau D
Curr Med Res Opin; 2009 May; 25(5):1273-84. PubMed ID: 19366302
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach.
Pollock RF; Chubb B; Valentine WJ; Heller S
Diabetes Metab Syndr Obes; 2018; 11():217-226. PubMed ID: 29844693
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.
Ridderstråle M; Jensen MM; Gjesing RP; Niskanen L
J Med Econ; 2013; 16(4):468-78. PubMed ID: 23384160
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials.
Palmer AJ; Roze S; Valentine WJ; Smith I; Wittrup-Jensen KU
Curr Med Res Opin; 2004 Nov; 20(11):1729-46. PubMed ID: 15537473
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland.
Brändle M; Azoulay M; Greiner RA
Int J Clin Pharmacol Ther; 2011 Mar; 49(3):217-30. PubMed ID: 21329624
[TBL] [Abstract][Full Text] [Related]
7. Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States.
Valentine WJ; Erny-Albrecht KM; Ray JA; Roze S; Cobden D; Palmer AJ
Adv Ther; 2007; 24(2):273-90. PubMed ID: 17565917
[TBL] [Abstract][Full Text] [Related]
8. Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis.
Guillermin AL; Samyshkin Y; Wright D; Nguyen T; Villeneuve J
J Med Econ; 2011; 14(2):207-16. PubMed ID: 21361858
[TBL] [Abstract][Full Text] [Related]
9. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U100 in Patients with Type 1 and Type 2 Diabetes Mellitus in Serbia.
Lalić N; Russel-Szymczyk M; Culic M; Tikkanen CK; Chubb B
Diabetes Ther; 2018 Jun; 9(3):1201-1216. PubMed ID: 29700772
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective.
Mezquita-Raya P; Darbà J; Ascanio M; Ramírez de Arellano A
Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):587-595. PubMed ID: 28649881
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria.
Russel-Szymczyk M; Valov V; Savova A; Manova M
BMC Endocr Disord; 2019 Dec; 19(1):132. PubMed ID: 31796048
[TBL] [Abstract][Full Text] [Related]
13. Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis.
Lau E; Salem A; Chan JCN; So WY; Kong A; Lamotte M; Luk A
Cost Eff Resour Alloc; 2019; 17():13. PubMed ID: 31303866
[TBL] [Abstract][Full Text] [Related]
14. Comparing the efficacy and safety of insulin detemir versus neutral protamine hagedorn insulin in treatment of diabetes during pregnancy: a randomized, controlled study.
Ji J; He Z; Yang Z; Mi Y; Guo N; Zhao H; Gao J; Ma Z; Luo X; Han Z
BMJ Open Diabetes Res Care; 2020 Apr; 8(1):. PubMed ID: 32265255
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of sensor-augmented pump therapy with low glucose-suspend in patients with type 1 diabetes mellitus and high risk of hypoglycemia in Spain.
Conget I; Martín-Vaquero P; Roze S; Elías I; Pineda C; Álvarez M; Delbaere A; Ampudia-Blasco FJ
Endocrinol Diabetes Nutr (Engl Ed); 2018; 65(7):380-386. PubMed ID: 29789227
[TBL] [Abstract][Full Text] [Related]
16. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus.
Rys P; Wojciechowski P; Rogoz-Sitek A; Niesyczyński G; Lis J; Syta A; Malecki MT
Acta Diabetol; 2015 Aug; 52(4):649-62. PubMed ID: 25585592
[TBL] [Abstract][Full Text] [Related]
17. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand.
Permsuwan U; Chaiyakunapruk N; Dilokthornsakul P; Thavorn K; Saokaew S
Appl Health Econ Health Policy; 2016 Jun; 14(3):281-92. PubMed ID: 26961276
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of continuous glucose monitoring with FreeStyle Libre
Bahia L; Mello KF; Lemos LLP; Costa NL; Mulinari E; Malerbi DA
Diabetol Metab Syndr; 2023 Nov; 15(1):242. PubMed ID: 38001509
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naïve Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia.
Shafie AA; Ng CH
Clinicoecon Outcomes Res; 2020; 12():333-343. PubMed ID: 32606850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
